Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 34
Filter
1.
Zhonghua Er Ke Za Zhi ; 62(9): 877-882, 2024 Sep 02.
Article in Chinese | MEDLINE | ID: mdl-39192447

ABSTRACT

Objective: To summarize the clinical features and genetic characteristics of Congenital bile acid synthetic disorder type 3 (BASD3) disorder caused by CYP7B1 gene variation. Methods: This was a case series study. Clinical data and genetic results of 2 cases of congenital bile acid synthetic disorder type 3 caused by CYP7B1 gene variations in the Department of Infectious Diseases, Children's Hospital of Fudan University at Xiamen and Department of Pediatrics, Women and Children's Hospital, School of Medicine, Xiamen University from January 2021 to December 2023 were retrospectively collected and analyzed. Literature up to December 2023 was searched from electronic databases of China National Knowledge Infrastructure (CNKI), Wanfang Data and PubMed with the combined keywords of " Congenital bile acid synthetic disorder type 3""Oxysterol 7-alpha-hydroxylase""Oxysterol 7α-Hydroxylase Deficiency""BASD3" and "CYP7B1 liver" both in Chinese and English. The main clinical features and genetic characteristics of BASD3 disorder caused by CYP7B1 gene variations were summarized. Results: Two BASD3 patients, 1 male and 1 female, were admitted at the ages of 3 months and 18 days, and 2 months and 7 days, respectively. Both patients presented with neonatal cholestasis and hepatomegaly. Biochemical evidence indicated direct hyper-bilirubinemia with elevated aminotransferase levels, while gamma-glutamyltransferase (GGT) and total bile acid levels were normal or nearly normal. Patient 1 was a compound heterozygotes of the CYP7B1 gene variants c.525-526insCAAGTTGG(p.Asp176GInfs*15) and c.334C>T(p.Arg112Ter). Patient 1 jaundice resolved and liver function tests normalized after oral administration of chenodeoxycholic acid (CDCA). Patient 2 was homozygous for variant c.334C>T(p.Arg112Ter) in CYP7B1 gene. Patient 2 was in liver failure status already and not reactive to oral CDCA administration. Patient 2 received living-related liver transplantation for enhanced abdominal CT revealed a liver tumor likely vascular origin. Literature review revealed no cases of BASD3 reported in Chinese literature, including 2 patients in this study, while 12 patients (9 males and 3 females) were reported in 9 English literatures. All of the 12 manifested jaundice and hepatosplenomegaly in infancy, with cirrhosis, liver failure, kidney enlargement, hypoglycemia, and spontaneous bleeding in some cases, polycystic kidney disease was demonstrated in 5 cases of them. The c.334C>T (p.Arg112Ter) of the CYP7B1 gene was homozygous in 4 cases and compound heterozygous in 2 cases. Among the 12 children, 6 cases received CDCA treatment, while 6 cases not. Four survived with their native liver in the 6 cases who received CDCA therapy, while none in the 6 cases not received CDCA therapy. Conclusions: BASD3 is a rare hereditary cholestatic disorder. Markedly elevated levels of conjugated bilirubin and aminotransferases, with normal or nearly normal GGT and total bile acid levels can serve as diagnostic clue. c.334C>T is the most common pathogenic variant of the CYP7B1 gene. Timely administration of CDCA may save the liver.


Subject(s)
Cholestasis , Cytochrome P450 Family 7 , Mutation , Steroid Metabolism, Inborn Errors , Female , Humans , Infant , Infant, Newborn , Male , Bile Acids and Salts/metabolism , Bile Acids and Salts/blood , Cytochrome P450 Family 7/genetics , Liver/metabolism , Retrospective Studies , Steroid Hydroxylases , Cholestasis/diagnosis , Cholestasis/drug therapy , Cholestasis/genetics , Steroid Metabolism, Inborn Errors/diagnosis , Steroid Metabolism, Inborn Errors/drug therapy , Steroid Metabolism, Inborn Errors/genetics
2.
Int J Mol Sci ; 25(9)2024 Apr 27.
Article in English | MEDLINE | ID: mdl-38731981

ABSTRACT

We aimed to analyze the association between CYP7B1 and prostate cancer, along with its association with proteins involved in cancer and metabolic processes. A retrospective analysis was performed on 390 patients with prostate cancer (PC) or benign prostatic hyperplasia (BPH). We investigated the interactions between CYP7B1 expression and proteins associated with PC and metabolic processes, followed by an analysis of the risk of biochemical recurrence based on CYP7B1 expression. Of the 139 patients with elevated CYP7B1 expression, 92.8% had prostate cancer. Overall, no increased risk of biochemical recurrence was associated with CYP7B1 expression. However, in a non-diabetic subgroup analysis, higher CYP7B1 expression indicated a higher risk of biochemical recurrence, with an HR of 1.78 (CI: 1.0-3.2, p = 0.05). PC is associated with elevated CYP7B1 expression. In a subgroup analysis of non-diabetic patients, elevated CYP7B1 expression was associated with an increased risk of biochemical recurrence, suggesting increased cancer aggressiveness.


Subject(s)
Biomarkers, Tumor , Cytochrome P450 Family 7 , Prostatic Neoplasms , Humans , Male , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/genetics , Biomarkers, Tumor/metabolism , Aged , Cytochrome P450 Family 7/metabolism , Cytochrome P450 Family 7/genetics , Middle Aged , Disease Progression , Retrospective Studies , Prostatic Hyperplasia/metabolism , Prostatic Hyperplasia/pathology , Immunohistochemistry , Tissue Array Analysis , Neoplasm Recurrence, Local/metabolism , Steroid Hydroxylases
4.
Int J Mol Sci ; 23(5)2022 Feb 22.
Article in English | MEDLINE | ID: mdl-35269552

ABSTRACT

(1) Background: Synovial fluid (SF) from knee joints with osteoarthritis (OA) has increased levels of phospholipids (PL). We have reported earlier that TGF-ß and IGF-1 stimulate fibroblast-like synoviocytes (FLS) to synthesize increased amounts of PLs. The current study examined whether IL-1ß induces the release of PLs in FLS and the underlying mechanism. (2) Methods: Cultured human OA FLS were treated with IL-1ß alone and with pathway inhibitors or with synthetic liver X receptor (LXR) agonists. Cholesterol hydroxylases, ABC transporters, apolipoproteins (APO), LXR, sterol regulatory binding proteins (SREBPs), and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) were analyzed by RT-PCR, Western blot, and ELISA. The release of radiolabeled PLs from FLS was determined, and statistical analysis was performed using R (N = 5-9). (3) Results: Like synthetic LXR agonists, IL-1ß induced a 1.4-fold greater release of PLs from FLS. Simultaneously, IL-1ß upregulated the level of the PL transporter ABCA1 and of cholesterol hydroxylases CH25H and CYP7B1. IL-1ß and T0901317 stimulated the expression of SREBP1c, whereas only T0901317 enhanced SREBP2, HMGCR, APOE, LXRα, and ABCG1 additionally. (4) Conclusions: IL-1ß partially controls PL levels in OA-SF by affecting the release of PLs from FLS. Our data show that IL-1ß upregulates cholesterol hydroxylases and thus the formation of oxysterols, which, as natural agonists of LXR, increase the level of active ABCA1, in turn enhancing the release of PLs.


Subject(s)
Benzoates/pharmacology , Benzylamines/pharmacology , Interleukin-1beta/pharmacology , Osteoarthritis/metabolism , Phospholipids/metabolism , Synoviocytes/cytology , ATP Binding Cassette Transporter 1/genetics , Cells, Cultured , Cytochrome P450 Family 7/genetics , Gene Expression Regulation/drug effects , Humans , Liver X Receptors/genetics , Osteoarthritis/genetics , Steroid Hydroxylases/genetics , Synovial Fluid/cytology , Synovial Fluid/drug effects , Synovial Fluid/metabolism , Synoviocytes/drug effects , Synoviocytes/metabolism
5.
Exp Cell Res ; 410(1): 112952, 2022 01 01.
Article in English | MEDLINE | ID: mdl-34848206

ABSTRACT

Septic arthritis induced by Staphylococcus aureus (S. aureus) causes irreversible cartilage degradation and subsequent permanent joint dysfunction. Recently, cartilage degradation in osteoarthritis is recognized to be associated with metabolic disorders. However, whether cholesterol metabolism is linked to septic arthritis pathology remains largely unknown. Here, we found that exposure to fermentation supernatant (FS) of S. aureus in chondrocytes resulted in a significant increase in expression of key modulators involved in cholesterol metabolism, including lectin-type oxidized low density lipoprotein receptor 1 (LOX1), cholesterol 25-hydroxylase (CH25H), 25- hydroxycholesterol 7α-hydroxylase (CYP7B1) as well as retinoic acid-related orphan receptor alpha (RORα), a binding receptor for cholesterol metabolites. We further demonstrated that enhancement of CH25H/CYP7B1/RORα axis resulted from FS exposure was mediated by activation of NF-κB signaling, along with upregulation in catabolic factors including matrix metallopeptidases (MMP3 and MMP13), aggrecanase-2 (ADAMTS5), and nitric oxide synthase-2 (NOS2) in chondrocytes. Exogenous cholesterol acts synergistically with FS in activating NF-κB pathway and increases cholesterol metabolism. While, the addition of tauroursodeoxycholic acid (TUDCA) which promotes cholesterol efflux, resulted in remarkable reduction of intracellular cholesterol level and restoration of balance between anabolism and catabolism in FS treated chondrocytes. Collectively, our data indicated that, in response to FS of S. aureus, NF-κB signaling activation coupled with increased cholesterol metabolism to stimulate catabolic factors in chondrocytes, highlighting cholesterol metabolism as a potential therapeutic target for treating septic arthritis.


Subject(s)
Arthritis, Infectious/genetics , Cartilage/growth & development , Osteoarthritis/genetics , Staphylococcus aureus/pathogenicity , ADAMTS5 Protein/genetics , Arthritis, Infectious/microbiology , Arthritis, Infectious/pathology , Cartilage/metabolism , Cartilage/microbiology , Cartilage/pathology , Cells, Cultured , Cholesterol/genetics , Chondrocytes/metabolism , Chondrocytes/microbiology , Chondrocytes/pathology , Cytochrome P450 Family 7/genetics , Gene Expression Regulation/genetics , Humans , Matrix Metalloproteinase 13/genetics , Metabolism/genetics , NF-kappa B/genetics , Nitric Oxide Synthase Type II/genetics , Nuclear Receptor Subfamily 1, Group F, Member 1/genetics , Osteoarthritis/microbiology , Osteoarthritis/pathology , Scavenger Receptors, Class E/genetics , Signal Transduction/genetics , Steroid Hydroxylases/genetics , Taurochenodeoxycholic Acid/genetics , Transcription Factor RelA/genetics
6.
Genes (Basel) ; 12(12)2021 11 25.
Article in English | MEDLINE | ID: mdl-34946825

ABSTRACT

Biallelic mutations in the CYP7B1 gene lead to spastic paraplegia-5 (SPG5). We report herein the case of a patient whose clinical symptoms began with progressive lower limb spasticity during childhood, and who secondly developed amyotrophic lateral sclerosis/frontotemporal dementia (ALS/FTD) at the age of 67 years. Hereditary spastic paraplegia (HSP) gene analysis identified the compound heterozygous mutations c.825T>A (pTyr275*) and c.1193C>T (pPro398Leu) in CYP7B1 gene. No other pathogenic variant in frequent ALS/FTD causative genes was found. The CYP7B1 gene seems, therefore, to be the third gene associated with the phenoconversion from HSP to ALS, after the recently described UBQLN2 and ERLIN2 genes. We therefore expand the phenotype associated with CYP7B1 biallelic mutations and make an assumption about a link between cholesterol dyshomeostasis and ALS/FTD.


Subject(s)
Amyotrophic Lateral Sclerosis/genetics , Cytochrome P450 Family 7/genetics , Frontotemporal Dementia/genetics , Mutation/genetics , Paraplegia/genetics , Steroid Hydroxylases/genetics , Humans , Male , Middle Aged , Pedigree , Phenotype
7.
Neurosci Lett ; 761: 136108, 2021 09 14.
Article in English | MEDLINE | ID: mdl-34256108

ABSTRACT

Spastic paraplegias (SPGs) are a group of clinically and genetically heterogeneous neurodegenerative diseases. Mutations in 78 genes have been identified in autosomal dominant hereditary SPG (AD-HSP) and autosomal recessive hereditary SPG (AR-HSP). Compared to familial HSP, much less is known about the genetic and clinical profiles of sporadic SPGs. In this study, we have screened mutations for 18 sporadic SPGs or AR-HSP patients (mainly Northern Chinese) by whole-exome sequencing. We identified 12 mutations in five genes in 9 (50%) patients, including 9 novel ones: SPG5A/CYP7B1 (c.851C > A; c.122 + 2 T > G), SPG11/KIAA1840 (c.1735 + 3_ 1735 + 6del AAGT); SPG7/SPG7 (c.1454G > A; c.1892_ 1906dup GAGGACGGGCCTCGG); SPG39/PNPLA6 (c.1591G > A; c. 2990C > T); SPG15/ ZFYVE26 (c. 4804C > T; c. 4278 G > A). Among all the mutations, 7 were detected in the SPG5A and SPG11. Age at onset was significantly younger in cases with mutations (15.45 ± 6.78 years) than those without mutations (25.56 ± 10.90 years) (P = 0.03). Except for two cases with the SPG5A mutations, all cases presented with complicated SPGs. Three cases carrying mutations in SPG7, SPG15, SPG39 showed symptoms and signs of ataxia. One case carrying the homozygous c.259 + 2 T > C mutation in CYP7B1 showed serum parameters indicating liver impairment. Magnetic resonance imaging showed significantly thinned corpus callosum in cases with SPG11 and SPG15, but not in those with SPG5A, SPG7 or SPG39. In contrast, cerebellar atrophy was prominent in the SPG7 and SPG39 cases. These findings expand the spectrum of genetic, clinical and imaging features of sporadic SPG and AR-HSP, and have important implications in genetic counselling, molecular mechanisms and precise diagnosis of the disease.


Subject(s)
Mutation Rate , Spastic Paraplegia, Hereditary/genetics , Adolescent , Adult , Cerebellum/diagnostic imaging , Corpus Callosum/diagnostic imaging , Cytochrome P450 Family 7/genetics , Female , Humans , Liver/diagnostic imaging , Magnetic Resonance Imaging , Male , Proteins/genetics , Spastic Paraplegia, Hereditary/diagnostic imaging , Spastic Paraplegia, Hereditary/pathology , Steroid Hydroxylases/genetics
8.
J Neurogenet ; 35(2): 84-94, 2021.
Article in English | MEDLINE | ID: mdl-33771085

ABSTRACT

Hereditary spastic paraplegia (HSP) is a clinically and genetically heterogeneous neurodegenerative disorder, characterized by lower-limb spasticity and weakness. To date, more than 82 loci/genes (SPG1-SPG82) have been identified that contribute to the cause of HSP. Despite the use of next-generation sequencing-based methods, genetic-analysis has failed in the finding of causative genes in more than 50% of HSP patients, indicating a more significant heterogeneity and absence of a given phenotype-genotype correlation. Here, we performed whole-exome sequencing (WES) to identify HSP-causing genes in three unrelated-Iranian probands. Candidate variants were detected and confirmed in the probands and co-segregated in the family members. The phenotypic data gathered and compared with earlier cases with the same sub-types of disease. Three novel homozygous variants, c.978delT; p.Q327Kfs*39, c.A1208G; p.D403G and c.3811delT; p.S1271Lfs*44, in known HSP-causing genes including ENTPD1, CYP7B1, and ZFYVE26 were identified, respectively. Intra and interfamilial clinical variability were observed among affected individuals. Mutations in CYP7B1 and ZFYVE26 are relatively common causes of HSP and associated with SPG5A and SPG15, respectively. However, mutations in ENTPD1 are related to SPG64 which is an ultra-rare form of HSP. The research affirmed more complexities of phenotypic manifestations and allelic heterogeneity in HSP. Due to these complexities, it is not feasible to show a clear phenotype-genotype correlation in HSP cases. Identification of more families with mutations in HSP-causing genes may help the establishment of this correlation, further understanding of the molecular basis of the disease, and would provide an opportunity for genetic-counseling in these families.


Subject(s)
Apyrase/genetics , Carrier Proteins/genetics , Cytochrome P450 Family 7/genetics , Spastic Paraplegia, Hereditary/genetics , Steroid Hydroxylases/genetics , Adolescent , Adult , Child , Child, Preschool , Female , Humans , Male , Mutation , Pedigree , Phenotype , Spastic Paraplegia, Hereditary/physiopathology , Exome Sequencing , Young Adult
9.
Dig Dis Sci ; 66(11): 3885-3892, 2021 11.
Article in English | MEDLINE | ID: mdl-33385262

ABSTRACT

BACKGROUND: We encountered 7 Japanese patients with bile acid synthesis disorders (BASD) including 3ß-hydroxy-Δ5-C27-steroid dehydrogenase/isomerase (3ß-HSD) deficiency (n = 3), Δ4-3-oxosteroid 5ß-reductase (5ß-reductase) deficiency (n = 3), and oxysterol 7α-hydroxylase deficiency (n = 1) over 21 years between 1996 and 2017. AIM: We aimed to clarify long-term outcome in the 7 patients with BASD as well as long-term efficacy of chenodeoxycholic acid (CDCA) treatment in the 5 patients with 3ß-HSD deficiency or 5ß-reductase deficiency. METHODS: Diagnoses were made from bile acid and genetic analyses. Bile acid analysis in serum and urine was performed using gas chromatography-mass spectrometry. Clinical and laboratory findings and bile acid profiles at diagnosis and most recent visit were retrospectively obtained from medical records. Long-term outcome included follow-up duration, treatments, growth, education/employment, complications of treatment, and other problems. RESULTS: Medians with ranges of current patient ages and duration of CDCA treatment are 10 years (8 to 43) and 10 years (8 to 21), respectively. All 7 patients, who had homozygous or compound heterozygous mutations in the HSD3B7, SRD5B1, or CYP7B1 gene, are currently in good health without liver dysfunction. In the 5 patients with CDCA treatment, hepatic function gradually improved following initiation. No adverse effects were noted. CONCLUSIONS: We concluded that CDCA treatment is effective in 3ß-HSD deficiency and 5ß-reductase deficiency, as cholic acid has been in other countries. BASD carry a good prognosis following early diagnosis and initiation of long-term CDCA treatment.


Subject(s)
Adrenal Hyperplasia, Congenital/drug therapy , Adrenal Hyperplasia, Congenital/genetics , Bile Acids and Salts/biosynthesis , Chenodeoxycholic Acid/therapeutic use , Cytochrome P450 Family 7/metabolism , Oxidoreductases/genetics , Steroid Hydroxylases/metabolism , Adolescent , Adult , Child , Cytochrome P450 Family 7/genetics , Gene Expression Regulation, Enzymologic/drug effects , Genetic Predisposition to Disease , Humans , Japan , Mutation , Steroid Hydroxylases/genetics , Young Adult
10.
Ann Clin Transl Neurol ; 7(4): 486-496, 2020 04.
Article in English | MEDLINE | ID: mdl-32202070

ABSTRACT

OBJECTIVES: To investigate the clinical, electrophysiological, neuroimaging characteristics and genetic features of SPG5 in Taiwan. METHODS: Mutational analysis of the coding regions of CYP7B1 was performed by utilizing targeted resequencing analysis of the 187 unrelated Taiwanese HSP patients. The diagnosis of SPG5 was ascertained by the presence of biallelic CYP7B1 mutations. The SPG5 patients received clinical, electrophysiological, and neuroimaging evaluations. Disease severity was assessed by using the Spastic Paraplegia Rating Scale (SPRS) and the disability score. Two microsatellite markers as well as 18 single-nucleotide polymorphism (SNP) markers flanking CYP7B1 were genotyped to assess the founder effect of the CYP7B1 p.R112* mutation. RESULTS: Nineteen SPG5 patients from 17 families were identified. They typically presented an insidious onset progressive spastic paraparesis with proprioception involvement beginning at age 8 to 40 years. Their MRIs often showed white matter abnormalities in bilateral occipito-parietal regions, spinal cord atrophy, and mild cerebellar atrophy. Six different mutations in CYP7B1 were recognized, including three novel ones (p.N131Ifs*4, p.A295V, and p.L439R). CYP7B1 p.R112* was the most common mutation and present in 88.2% of the 17 SPG5 pedigrees. The patients with homozygous CYP7B1 p.R112* mutations had a milder clinical severity. Detailed haplotype analyses demonstrated a shared haplotype in the 25 individuals carrying at least one single allele of CYP7B1 p.R112*, suggesting a founder effect. INTERPRETATION: This study delineates the distinct clinical and genetic features of SPG5 in Taiwan and provides useful information for the diagnosis and management of SPG5, especially in patients of Chinese descent.


Subject(s)
Brain/pathology , Cytochrome P450 Family 7/genetics , Proprioception/physiology , Spastic Paraplegia, Hereditary , Steroid Hydroxylases/genetics , Adult , Age of Onset , Aged , Brain/diagnostic imaging , Female , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Severity of Illness Index , Spastic Paraplegia, Hereditary/epidemiology , Spastic Paraplegia, Hereditary/genetics , Spastic Paraplegia, Hereditary/pathology , Spastic Paraplegia, Hereditary/physiopathology , Taiwan/epidemiology , Young Adult
11.
J Mol Endocrinol ; 64(3): 165-179, 2020 04.
Article in English | MEDLINE | ID: mdl-31990658

ABSTRACT

Many sex differences in liver gene expression originate in the brain, depend on GH secretion and may underlie sex disparities in hepatic disease. Because epigenetic mechanisms may contribute, we studied promoter methylation and microRNA abundance in the liver, associated with expression of sexual dimorphic genes in mice with selective disruption of the dopamine D2 receptor in neurons (neuroDrd2KO), which decreases hypothalamic Ghrh, pituitary GH, and serum IGFI and in neonatally androgenized female mice which have increased pituitary GH content and serum IGFI. We evaluated mRNA levels of the female predominant genes prolactin receptor (Prlr), alcohol dehydrogenase 1 (Adh1), Cyp2a4, and hepatocyte nuclear transcription factor 6 (Hnf6) and the male predominant gene, Cyp7b1. Female predominant genes had higher mRNA levels compared to males, but lower methylation was only detected in the Prlr and Cyp2a4 female promoters. In neuroDrd2KO mice, sexual dimorphism was lost for all genes; the upregulation (feminization) of Prlr and Cyp2a4 in males correlated with decreased methylation of their promoters, and the downregulation (masculinization) of Hnf-6 mRNA in females correlated inversely with its promoter methylation. Neonatal androgenization of females evoked a loss of sexual dimorphism only for the female predominant Hnf6 and Adh1 genes, but no differences in promoter methylation were found. Finally, mmu-miR-155-5p, predicted to target Cyp7b1 expression, was lower in males in association with higher Cyp7b1 mRNA levels compared to females and was not modified in neuroDrd2KO or TP mice. Our results suggest specific regulation of gene sexually dimorphic expression in the liver by methylation or miRNAs.


Subject(s)
Alcohol Dehydrogenase/genetics , Aryl Hydrocarbon Hydroxylases/genetics , Cytochrome P450 Family 2/genetics , Cytochrome P450 Family 7/genetics , Growth Hormone/pharmacology , Hepatocyte Nuclear Factor 6/genetics , Receptors, Prolactin/genetics , Steroid Hydroxylases/genetics , Alcohol Dehydrogenase/metabolism , Animals , Aryl Hydrocarbon Hydroxylases/metabolism , Cytochrome P450 Family 2/metabolism , Cytochrome P450 Family 7/metabolism , Epigenesis, Genetic/drug effects , Epigenesis, Genetic/physiology , Female , Gene Expression Regulation/drug effects , Growth Hormone/metabolism , Hepatocyte Nuclear Factor 6/metabolism , Liver/drug effects , Liver/metabolism , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Promoter Regions, Genetic/genetics , Receptors, Prolactin/metabolism , Sex Characteristics , Signal Transduction/drug effects , Signal Transduction/genetics , Steroid Hydroxylases/metabolism
12.
Pediatr Neonatol ; 61(1): 75-83, 2020 02.
Article in English | MEDLINE | ID: mdl-31337596

ABSTRACT

BACKGROUND: Inborn errors of bile acid metabolism (IEBAM) cause rare but treatable genetic disorders that can present as neonatal cholestasis or neurological diseases. Without timely primary bile acid treatment, patients may develop liver failure early in life. This study aimed to analyze the types and treatment outcomes of IEBAM in Taiwanese infants and document the allele frequency of CYP7B1 hot spot mutations in the population. METHODS: Urine samples from patients with infantile intrahepatic cholestasis and suspected IEBAM were subjected to urinary bile acid analysis by gas chromatography-mass spectrometry (GC/MS). Genetic diagnoses were made using direct sequencing or next-generation sequencing. We also tested healthy control subjects for a probable hot spot point mutation of CYP7B1. RESULTS: Among the 75 patients with infantile intrahepatic cholestasis tested during 2000 -2016, three had ∆4-3-oxosteroid 5ß-reductase deficiency with AKR1D1 mutations, and three had oxysterol-7α-hydroxylase deficiency with CYP7B1 mutation. Two patients with ∆4-3-oxosteroid 5ß-reductase deficiency were successfully treated with cholic acid. The three unrelated infants with oxysterol 7α-hydroxylase deficiencies had the same p.R112X homozygous CYP7B1 mutation. Two had mild renal or neurological involvement. Among 608 healthy control subjects, the allele frequency of the heterozygous mutation for p.R112X was 2/1216 (0.16%). The only surviving patient with oxysterol 7α-hydroxylase deficiency recovered from liver failure after chenodeoxycholic acid (CDCA) treatment beginning at 3 months of age. CONCLUSION: Distinct types of IEBAM disease were found in the Taiwanese population. Patients with early diagnosis and early treatment had a favorable outcome. IEBAM prevalence rates may be higher than expected due to the presence of heterozygous mutations in the general population.


Subject(s)
Bile Acids and Salts/metabolism , Cytochrome P450 Family 7/genetics , Metabolism, Inborn Errors/genetics , Mutation , Oxidoreductases/genetics , Steroid Hydroxylases/genetics , Female , Humans , Infant , Male , Metabolism, Inborn Errors/diagnosis
13.
Cell Cycle ; 18(23): 3337-3350, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31599189

ABSTRACT

Gallbladder cancer (GBC) is the common malignancy of the bile tract system with extremely poor clinical outcomes, owing to its metastatic property and intrinsic resistance to the first-line drugs. Although it is well-established that cholesterol abnormity contributes to gallstone formation, a leading risk factor for GBC, the link of cholesterol homeostasis with GBC has not been investigated. The present study systematically examined the genes implicated in cholesterol homeostasis, and revealed altered gene expressions of de novo cholesterol biosynthesis and sterol sulfonation (SULT2B1), reduced bile acid synthesis (CYP7B1 and CYP39A1) and impaired sterol efflux (ABCA1, ABCG5, LCAT, and CETP) in GBC tissues. Suppression of cholesterol biosynthesis by lovastatin inhibited GBC cell proliferation possibly through attenuating the DNA repair process. Further investigation revealed lovastatin sensitized GBC cells to cisplatin-induced apoptosis and suppressed the activation of CHK1, CHK2, and H2AX during DNA damage response. By using chemically distinct statins, HMGCR depletion or supplementing mevalonate, the product of HMGCR, we showed the inhibitory effects on DNA repair process of lovastatin were due to the blockage of the mevalonate pathway. Subcutaneous xenograft mice model suggested lovastatin promoted the therapeutic efficacy of cisplatin, and significantly prolonged the survival times of tumor-bearing mice. Moreover, HMGCR ablation repressed tumor growth in vivo, which can be rescued partially by restored expression of HMGCR, suggesting the on-target effects of lovastatin. Therefore, our study provides the clinical relevance of cholesterol homeostasis with GBC progression, and highlights a novel intervention of combined use of lovastatin and cisplatin for GBC.


Subject(s)
Cholesterol/genetics , Cisplatin/adverse effects , Gallbladder Neoplasms/drug therapy , Gallstones/drug therapy , ATP Binding Cassette Transporter 1/genetics , ATP Binding Cassette Transporter, Subfamily G, Member 5/genetics , Animals , Apoptosis/drug effects , Cholesterol/biosynthesis , Cholesterol Ester Transfer Proteins/genetics , Cisplatin/pharmacology , Cytochrome P450 Family 7/genetics , DNA Damage/drug effects , DNA Repair/drug effects , Female , Gallbladder Neoplasms/genetics , Gallbladder Neoplasms/pathology , Gallstones/genetics , Gallstones/pathology , Heterografts , Humans , Male , Mice , Phosphatidylcholine-Sterol O-Acyltransferase/genetics , Risk Factors , Steroid Hydroxylases/genetics , Sulfotransferases/genetics
14.
Endocrinology ; 160(10): 2485-2494, 2019 10 01.
Article in English | MEDLINE | ID: mdl-31386147

ABSTRACT

27-Hydroxycholesterol (27HC) is an abundant cholesterol metabolite and has detrimental effects on the cardiovascular system, whereas its impact on adiposity is not well known. In this study, we found that elevations in 27HC cause increased body weight gain in mice fed a high-fat/high-cholesterol diet in an estrogen receptor α-dependent manner. Regardless of diet type, body fat mass was increased by 27HC without changes in food intake or fat absorption. 27HC did not alter energy expenditure in mice fed a normal chow diet and increased visceral white adipose mass by inducing hyperplasia but not hypertrophy. Although 27HC did not augment adipocyte terminal differentiation, it increased the adipose cell population that differentiates to mature adipocytes. RNA sequencing analysis revealed that 27HC treatment of mice fed a normal chow diet induces inflammatory gene sets similar to those seen after high-fat/high-cholesterol diet feeding, whereas there was no overlap in inflammatory gene expression among any other 27HC administration/diet change combination. Histological analysis showed that 27HC treatment increased the number of total and M1-type macrophages in white adipose tissues. Thus, 27HC promotes adiposity by directly affecting white adipose tissues and by increasing adipose inflammatory responses. Lowering serum 27HC levels may lead to an approach targeting cholesterol to prevent diet-induced obesity.


Subject(s)
Adipogenesis/drug effects , Adiposity/drug effects , Dietary Fats/adverse effects , Hydroxycholesterols , Obesity/chemically induced , Animals , Cytochrome P450 Family 7/genetics , Cytochrome P450 Family 7/metabolism , Diet, High-Fat/adverse effects , Dietary Fats/pharmacology , Female , Gene Expression Regulation/drug effects , Inflammation/chemically induced , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Signal Transduction/drug effects , Steroid Hydroxylases/genetics , Steroid Hydroxylases/metabolism
15.
Sci Rep ; 9(1): 10260, 2019 07 16.
Article in English | MEDLINE | ID: mdl-31311983

ABSTRACT

Cholesterol mediates its proliferative and metastatic effects via the metabolite 27-hydroxycholesterol (27-HC), at least in breast and endometrial cancer. We determined the serum lipoprotein profile, intratumoral cholesterol and 27-HC levels in a cohort of patients with well-differentiated papillary thyroid carcinoma (PTC; low/intermediate and high risk), advanced thyroid cancers (poorly differentiated, PDTC and anaplastic thyroid carcinoma, ATC) and benign thyroid tumors, as well as the expression of genes involved in cholesterol metabolism. We investigated the gene expression profile, cellular proliferation, and migration in Nthy-ori 3.1 and CAL-62 cell lines loaded with human low-density lipoprotein (LDL). Patients with more aggressive tumors (high-risk PTC and PDTC/ATC) showed a decrease in blood LDL cholesterol and apolipoprotein B. These changes were associated with an increase in the expression of the thyroid's LDL receptor, whereas 3-hydroxy-3-methylglutaryl-CoA reductase and 25-hydroxycholesterol 7-alpha-hydroxylase were downregulated, with an intratumoral increase of the 27-HC metabolite. Furthermore, LDL promoted proliferation in both the Nthy-ori 3.1 and CAL-62 thyroid cellular models, but only in ATC cells was its cellular migration increased significantly. We conclude that cholesterol and intratumoral accumulation of 27-HC promote the aggressive behavior process of PTC. Targeting cholesterol metabolism could be a new therapeutic strategy in thyroid tumors with poor prognosis.


Subject(s)
Carcinoma, Papillary/pathology , Cholesterol, LDL/blood , Hydroxycholesterols/metabolism , Thyroid Neoplasms/pathology , Adolescent , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/blood , Carcinoma, Papillary/genetics , Carcinoma, Papillary/metabolism , Cell Line, Tumor , Cell Movement , Cell Proliferation , Cholestanetriol 26-Monooxygenase/genetics , Cytochrome P450 Family 7/genetics , Female , Gene Expression Regulation, Neoplastic , Humans , Hydroxymethylglutaryl CoA Reductases/genetics , MAP Kinase Signaling System , Male , Middle Aged , Phosphatidylinositol 3-Kinases/metabolism , Receptors, LDL/genetics , Steroid Hydroxylases/genetics , TOR Serine-Threonine Kinases/metabolism , Thyroid Carcinoma, Anaplastic/genetics , Thyroid Carcinoma, Anaplastic/metabolism , Thyroid Carcinoma, Anaplastic/pathology , Thyroid Neoplasms/genetics , Thyroid Neoplasms/metabolism , Young Adult
16.
Biomolecules ; 9(4)2019 04 13.
Article in English | MEDLINE | ID: mdl-31013940

ABSTRACT

Deficiency in cytochrome P450 (CYP) 7B1, also known as oxysterol 7α-hydroxylase, in humans leads to hereditary spastic paraplegia type 5 (SPG5) and in some cases in infants to liver disease. SPG5 is medically characterized by loss of motor neurons in the corticospinal tract. In an effort to gain a better understanding of the fundamental biochemistry of this disorder, we have extended our previous profiling of the oxysterol content of brain and plasma of Cyp7b1 knockout (-/-) mice to include, amongst other sterols, 25-hydroxylated cholesterol metabolites. Although brain cholesterol levels do not differ between wild-type (wt) and knockout mice, we find, using a charge-tagging methodology in combination with liquid chromatography-mass spectrometry (LC-MS) and multistage fragmentation (MSn), that there is a build-up of the CYP7B1 substrate 25-hydroxycholesterol (25-HC) in Cyp7b1-/- mouse brain and plasma. As reported earlier, levels of (25R)26-hydroxycholesterol (26-HC), 3ß-hydroxycholest-5-en-(25R)26-oic acid and 24S,25-epoxycholesterol (24S,25-EC) are similarly elevated in brain and plasma. Side-chain oxysterols including 25-HC, 26-HC and 24S,25-EC are known to bind to INSIG (insulin-induced gene) and inhibit the processing of SREBP-2 (sterol regulatory element-binding protein-2) to its active form as a master regulator of cholesterol biosynthesis. We suggest the concentration of cholesterol in brain of the Cyp7b1-/- mouse is maintained by balancing reduced metabolism, as a consequence of a loss in CYP7B1, with reduced biosynthesis. The Cyp7b1-/- mouse does not show a motor defect; whether the defect in humans is a consequence of less efficient homeostasis of cholesterol in brain has yet to be uncovered.


Subject(s)
Brain/metabolism , Cytochrome P450 Family 7/genetics , Hydroxycholesterols/metabolism , Spastic Paraplegia, Hereditary/metabolism , Steroid Hydroxylases/genetics , Animals , Cytochrome P450 Family 7/deficiency , Hydroxycholesterols/blood , Male , Mice , Spastic Paraplegia, Hereditary/blood , Spastic Paraplegia, Hereditary/genetics , Steroid Hydroxylases/deficiency
17.
Intern Med ; 58(5): 719-722, 2019 Mar 01.
Article in English | MEDLINE | ID: mdl-30333426

ABSTRACT

SPG5 is a rare subtype of autosomal recessive hereditary spastic paraplegia caused by a homozygous mutation in the oxysterol 7α-hydroxylase gene, CYP7B1. We describe the first Japanese patient with SPG5 with a novel mutation in the CYP7B1 gene. On exome sequencing, we identified a homozygous frameshift mutation, c.741delA, p.K247fs, in exon 3 of the CYP7B1 gene. The patient showed spastic paraparesis with white matter hyperintensities in the bilateral corona radiata and periventricular and subcortical regions on brain magnetic resonance imaging. The present study expands the mutation spectrum of CYP7B1 and provides an opportunity to study the genotype-phenotype correlation in SPG5.


Subject(s)
Cytochrome P450 Family 7/genetics , Frameshift Mutation , Spastic Paraplegia, Hereditary/genetics , Steroid Hydroxylases/genetics , Aged , Brain/diagnostic imaging , Disease Progression , Exome/genetics , Exons/genetics , Female , Homozygote , Humans , Magnetic Resonance Imaging/methods , Spastic Paraplegia, Hereditary/diagnostic imaging , Exome Sequencing/methods
18.
J Korean Med Sci ; 33(51): e324, 2018 Dec 17.
Article in English | MEDLINE | ID: mdl-30546280

ABSTRACT

Oxysterol 7α-hydroxylase deficiency is a very rare liver disease categorized as inborn errors of bile acid synthesis, caused by CYP7B1 mutations. As it may cause rapid progression to end-stage liver disease even in early infancy, a high index of suspicion is required to prevent fatal outcomes. We describe the case of a 3-month-old boy with progressive cholestatic hepatitis and severe hepatic fibrosis. After excluding other etiologies for his early liver failure, we found that he had profuse urinary excretion of 3ß-monohydroxy-Δ5-bile acid derivatives by gas chromatography/mass spectrometry analysis with dried urine spots on filter paper. He was confirmed to have a compound heterozygous mutation (p.Arg388Ter and p.Tyr469IlefsX5) of the CYP7B1 gene. After undergoing liver transplantation (LT) from his mother at 4 months of age, his deteriorated liver function completely normalized, and he had normal growth and development until the current follow-up at 33 months of age. We report the first Korean case of oxysterol 7α-hydroxylase deficiency in the youngest infant reported to undergo successful living donor LT to date.


Subject(s)
Cytochrome P450 Family 7/genetics , Liver Failure/therapy , Liver Transplantation , Steroid Hydroxylases/genetics , Bile Acids and Salts/analysis , DNA Mutational Analysis , Gas Chromatography-Mass Spectrometry , Humans , Infant , Liver Failure/diagnosis , Liver Failure/genetics , Liver Failure/pathology , Living Donors , Male , Polymorphism, Single Nucleotide , Republic of Korea , Steroid Metabolism, Inborn Errors/diagnosis , Steroid Metabolism, Inborn Errors/therapy
19.
PLoS One ; 13(7): e0199682, 2018.
Article in English | MEDLINE | ID: mdl-29965978

ABSTRACT

Stearoyl-CoA desaturase 1 (SCD1) catalyzes the rate limiting step in monounsaturated fatty acid synthesis by inserting a double bond at the delta-9 position of long-chain fatty acids. SCD1 converts stearate (18:0) to oleate (18:1n9) and palmitate (16:0) to palmitoleate (16:1n7), respectively. Mice with global and skin-specific deletion (SKO) of SCD1 exhibit increased whole body energy expenditure and protection against diet-induced adiposity, hepatic steatosis, insulin sensitivity and glucose intolerance. The mechanisms that link cutaneous lipid homeostasis with whole body energy balance are presently unknown. In this study, we reveal that SKO mice demonstrate increased skin surface free cholesterol, decreased circulating total cholesterol and increased taurine-conjugated and hydrophilic bile acids. Tauro-ß-muricholic acid, which is a marker of extrahepatic bile acid synthesis, is significantly elevated in SKO plasma. Bile acid signaling through the bile acid-specific receptor TGR5 is known to be protective against obesity and metabolic disease; a phenotype that is similar to SKO mice. We therefore examined TGR5 expression and its downstream mediator, DIO2, in various tissues and found that both TGR5 and DIO2 expression were significantly increased in brown adipose tissue. In sum, we suggest that skin-derived bile acids are involved in the lean and metabolically healthy phenotype of SKO mice.


Subject(s)
Bile Acids and Salts/blood , Bile Acids and Salts/chemistry , Obesity , Skin/enzymology , Stearoyl-CoA Desaturase/genetics , Stearoyl-CoA Desaturase/metabolism , Adipocytes/metabolism , Adipose Tissue/metabolism , Animals , Biomarkers , Cholesterol/metabolism , Cytochrome P450 Family 7/genetics , Hydrophobic and Hydrophilic Interactions , Male , Mice , Mice, Knockout , Organ Specificity , Sebaceous Glands/metabolism , Signal Transduction , Steatorrhea/genetics , Steatorrhea/metabolism , Steroid Hydroxylases/genetics , Thermogenesis/genetics
20.
Toxicol Lett ; 286: 48-53, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29357290

ABSTRACT

There have been many concerns about the possible adverse effects of thyroid hormone-disrupting chemicals in the environment. Because thyroid hormones are essential for regulating the growth and differentiation of many tissues, disruption of thyroid hormones during the neonatal period of an organism might lead to permanent effects on that organism. We postulated that there are target genes that are sensitive to thyroid hormones particularly during the neonatal period and that would thus be susceptible to thyroid hormone-disrupting chemicals. Global gene expression analysis was used to identify these genes in the liver of rat neonates. The changes in hepatic gene expression were examined 24 h after administering 1.0, 10, and 100 ng/g body weight (bw) triiodothyronine (T3) to male rats on postnatal day 3. Thirteen upregulated and four downregulated genes were identified in the neonatal liver. Among these, Pdp2 and Slc25a25 were found to be upregulated and more sensitive to T3 than the others, whereas Cyp7b1 and Hdc were found to be downregulated even at the lowest dose of 1.0 ng/g bw T3. Interestingly, when the responses of gene expression to T3 were examined in adult rats (8-week old), one-third of them did not respond to T3. The environmental chemicals with thyroid hormone-like activity, hydroxylated polybrominated diphenyl ethers, were then administered to neonatal rats to examine the effects on expression of the identified genes. The results showed that these chemicals were indeed capable of changing the expression of Slc25a25 and Hdc. Our results demonstrated a series of hepatic T3-responsive genes that are more sensitive to hormones during the neonatal period than during adulthood. These genes might be the potential targets of thyroid hormone-disrupting chemicals in newborns.


Subject(s)
Endocrine Disruptors/toxicity , Gene Expression Regulation/drug effects , Liver/drug effects , Triiodothyronine/pharmacology , Animals , Animals, Newborn , Cytochrome P450 Family 7/genetics , Cytochrome P450 Family 7/metabolism , Dose-Response Relationship, Drug , Gene Expression Profiling/methods , Histidine Decarboxylase/genetics , Histidine Decarboxylase/metabolism , Liver/metabolism , Male , Mitochondrial Membrane Transport Proteins/genetics , Mitochondrial Membrane Transport Proteins/metabolism , Oligonucleotide Array Sequence Analysis , Pyruvate Dehydrogenase (Lipoamide)-Phosphatase/genetics , Pyruvate Dehydrogenase (Lipoamide)-Phosphatase/metabolism , Rats, Inbred F344 , Risk Assessment , Steroid Hydroxylases/genetics , Steroid Hydroxylases/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL